Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Aims To compare the health and economic outcomes of using acarbose, an intensive lifestyle modification programme, metformin or no intervention to prevent progression to diabetes in Canadian individuals with impaired glucose tolerance (IGT). Methods A model was developed to simulate the course of individuals with IGT under each treatment strategy. Patients remain in the IGT state or transition from IGT to diabetes, to normal glucose tolerance (NGT) or to death. Effectiveness and resource use data were derived from published intervention trials. A comprehensive health‐care payer perspective incorporating all major direct costs, reported in 2000 Canadian dollars, was adopted. Results Over a decade, 70 of the 1000 untreated patients are expected to die and 542 develop diabetes. Intensive lifestyle modification is estimated to prevent 117 cases of diabetes, while metformin would prevent 52 and acarbose 74 cases. The proportion of those who return to NGT also increases with any treatment. While lifestyle modification is more effective, it can increase overall costs depending on how it is implemented, whereas acarbose and metformin reduce costs by nearly $1000 per patient. Lifestyle modification was cost effective, varying from $749/life year gained (LYG) vs. no treatment to about $10 000/LYG vs. acarbose. Acarbose costs somewhat more than metformin, but is more effective: $1798/LYG. Conclusion The results of this model suggest that the treatment of IGT in Canada is a cost‐effective way to prevent diabetes and may generate savings. While pharmacological treatments tended to be less costly, intensive lifestyle modification, if maintained, led to the greatest health benefits at reasonable incremental costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543
The Diabetes Prevention Program (DPP)
The Diabetes Prevention Program (DPP) Research Group (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2165 · Cited by 1,938
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624
Harris, M. I., Hadden, W. C., Knowler, W. C., & Bennett, P. H. (1987) · Diabetes · doi:10.2337/diab.36.4.523 · Cited by 1,096
Eriksson, J., Lindström, J., Valle, T., Aunola, S., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Lauhkonen, M., Lehto, P., et al. (1999) · Diabetologia · doi:10.1007/s001250051229 · Cited by 368
Cited by
Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review
Li, R., Zhang, P., Barker, L. E., Chowdhury, F. M., & Zhang, X. (2010) · Diabetes Care · doi:10.2337/dc10-0843 · Cited by 491
The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1468 · Cited by 436
“Although we (7) and others (8,9) suggested that lifestyle would be cost-effective or even cost-saving over the long term, one analysis suggested that it might be too expensive for health plans or a national program to implement (10).”
BackgroundGillies, C. L., Lambert, P. C., Abrams, K. R., Sutton, A. J., Cooper, N. J., Hsu, R. T., Davies, M. J., & Khunti, K. (2008) · BMJ · doi:10.1136/bmj.39545.585289.25 · Cited by 290
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
Hostalek, U., Gwilt, M., & Hildemann, S. (2015) · Drugs · doi:10.1007/s40265-015-0416-8 · Cited by 278
The Empirical Evidence for the Telemedicine Intervention in Diabetes Management
Bashshur, R. L., Shannon, G. W., Smith, B. R., & Woodward, M. A. (2015) · Telemedicine and e-Health · doi:10.1089/tmj.2015.0029 · Cited by 102
Metadata
- Authors
- Caro, J. J., Getsios, D., Caro, I., Klittich, W. S., & O'Brien, J. A.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2004-10-20
- Volume
- 21
- Issue
- 11
- Pages
- 1229-1236
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2138452846
- Cited by
- 67
- References
- 7
- FWCI
- 9.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.